December 13, 2021
Physician and Scientist, Serge Przedborski, Joins Luciole Pharmaceuticals' Science Advisory Board
NATICK, Mass., Dec. 13, 2021 /PRNewswire/ -- Luciole Pharmaceuticals, Inc is pleased to announce that Serge Przedborski, MD, Ph.D., is joining the company's scientific advisory board.
Dr. Przedborski, is the Page and William Black Professor of Neurology (in Pathology and Cell Biology and Neuroscience) at the Columbia University Irving Medical Center, and:
Co-Director, Motor Neuron Center
Vice Chair of Research, Department of Neurology
Director, Columbia Translational Neuroscience Initiative (CTNI)
Chief, Division of Movement Disorders
"Dr. Przedborski has the ideal combination of clinical and basic research interests and experience to support Luciole's goals of developing novel therapeutics targeting mitochondrial DNA to prevent the progression of devastating neurodegenerative diseases, like PD. We are very excited to have him join us on our mission" said Dennis I. Goldberg, Ph.D., President and CEO of Luciole Pharmaceuticals.
October 6, 2021
Luciole Pharmaceuticals and Cyclica Announce Research Collaboration to Accelerate Discovery of Novel Medicines
Natick, MA & Toronto, Canada - (October 06, 2021) – Luciole Pharmaceuticals, a startup company focused on the discovery and development of small molecules that enhance the repair of oxidative damage to mitochondrial DNA (mtDNA), and Cyclica , the partner of choice for data-driven drug discovery, today announced a research collaboration aimed at accelerating the discovery of small molecule agonists of OGG1 (8-oxoguanine DNA glycosylase), the key enzyme in initiation of base excision repair (BER) of both nuclear and mtDNA. Luciole will use Cyclica’s platform to screen, identify, design and evaluate compounds directed at OGG1 for the treatment of neurodegenerative and other diseases of aging.